I think the other thing, the third thing, that they're going to have to do, other than reassuring people that it's OK to be approving something the manufacturer doesn't seem that interested in approving and that's not going to become required, is they're going to have to be transparent and open about the benefits so that people can make an individual choice under this framework, which I'm sure will inevitably lead to a fourth dose being permitted in New Zealand. There's no doubt that the evolution of the COVID-19 virus—or, perhaps more properly, viruses—from one variant to the next has changed the underlying epidemiology, and therefore what is desirable policy. 